Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sinbaglustat (OGT2378) (OGT2378) 是葡萄糖神经酰胺合成酶 (GCS) 和非溶酶体葡萄糖神经酰胺酶 (GBA2) 的双重抑制剂。Sinbaglustat 是一种可透过血脑屏障的的口服N-烷基亚氨基糖。Sinbaglustat 可用于治疗溶酶体贮积症和研究溶酶体功能障碍相关的中枢神经退行性疾病。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,190 | 现货 | ||
5 mg | ¥ 2,980 | 现货 | ||
10 mg | ¥ 4,390 | 现货 | ||
25 mg | ¥ 6,880 | 现货 | ||
50 mg | ¥ 9,470 | 现货 | ||
100 mg | ¥ 12,700 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 2,670 | 现货 |
产品描述 | Sinbaglustat (OGT2378) (OGT2378) is a dual inhibitor of glucose ceramide synthetase (GCS) and non-lysosomal glucose ceramidase (GBA2).Sinbaglustat is an orally administered N-alkyl iminosugar that crosses the blood-brain barrier.Sinbaglustat is used for the treatment of lysosomal storage disorders and for the study of central neurodegenerative disorders associated with lysosomal dysfunction. Sinbaglustat is used for the treatment of lysosomal storage disorders and for the study of lysosomal dysfunction-related central neurodegenerative diseases. |
体外活性 |
Sinbaglustat (OGT2378) (20 μM) leads to a remarkable reduction in the synthesis of glucosylceramide by 93% and ganglioside by >95% when compared to untreated MEB4 cells. This reduction occurs without inducing any cytotoxicity or antiproliferative effects.[1] Sinbaglustat is 50-fold more potent in inhibiting GBA2 than GCS.[2] |
体内活性 | Sinbaglustat (OGT2378) (2500 mg/kg/day; p.o.; in the powdered chow; corresponding to 35-40 mg/mouse/day of Sinbaglustat; Female syngeneic C57BL/6 mice and bearing MEB4 melanoma tumor, 6-8 weeks old bearing MEB4 melanoma tumor) is highly effective in impeding melanoma tumor growth in vivo. The effectiveness of p.o. Sinbaglustat in this murine model suggests that inhibition of glycosphingolipid synthesis is a promising approach to inhibit tumor progression.[1] |
别名 | ACT-519276, Sinbaglustat, OGT2378 |
分子量 | 233.3 |
分子式 | C11H23NO4 |
CAS No. | 441061-33-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 46.66 mg/mL (200 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.2863 mL | 21.4316 mL | 42.8633 mL | 107.1582 mL |
5 mM | 0.8573 mL | 4.2863 mL | 8.5727 mL | 21.4316 mL | |
10 mM | 0.4286 mL | 2.1432 mL | 4.2863 mL | 10.7158 mL | |
20 mM | 0.2143 mL | 1.0716 mL | 2.1432 mL | 5.3579 mL | |
50 mM | 0.0857 mL | 0.4286 mL | 0.8573 mL | 2.1432 mL | |
100 mM | 0.0429 mL | 0.2143 mL | 0.4286 mL | 1.0716 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Sinbaglustat 441061-33-2 Metabolism Transferase OGT 2378 ACT-519276 ACT519276 OGT-2378 OGT2378 ACT 519276 Inhibitor inhibitor inhibit